Plaintiff
12 cases as plaintiff.
Omni Medsci Inc. is a privately held non-practicing entity (NPE) that asserts patents primarily related to medical device technology. The company was formed in Michigan in October 2010 and operates as a subsidiary of Omni Technology Holdings, Inc., which was established in Michigan in October 2013 and is under the control of its founder, Mohammed N. Islam. No specific employee count or revenue figures are publicly available for Omni Medsci Inc.
As an NPE, Omni Medsci Inc. does not manufacture or sell its own products, but instead seeks to commercialize its patent portfolio through partnerships and licensing. The asserted patents generally relate to medical diagnostic systems, including those controlled by voice commands, and medical device applications utilizing near-infrared or short-wave infrared light sources. The underlying optical technology and inventions are attributed to Mohammed N. Islam, a professor at the University of Michigan, with research interests spanning defense and healthcare applications.
Omni Medsci Inc. demonstrates an active patent-litigation posture, primarily as a patent enforcer. The company has initiated two plaintiff cases in the provided data, targeting companies like Whoop, Inc. in the Delaware District Court and Fossil et al. in the patent-plaintiff-friendly Eastern District of Texas. Concurrently, Omni Medsci Inc. has been a defendant in three cases before the Patent Trial and Appeal Board (PTAB), where its asserted patents have faced validity challenges from entities such as Unified Patents and SAMSUNG ELECTRONICS CO., LTD..
Notable cases include Omni Medsci, Inc. v. Fossil et al., filed in the Eastern District of Texas in late 2024, which also named OnePlus, Oura Health, and Samsung in related complaints, alleging infringement of patents covering wearable devices and physiological parameter measurement. Earlier litigation efforts by Omni Medsci Inc. have also included disputes with Apple Inc., where a federal judge invalidated a patent related to tracking blood-related metrics. Unified Patents has actively sought prior art for Omni Medsci's patents through crowdsourcing contests, characterizing Omni Medsci Inc. as an NPE.
Watchlist
Email-only, free, anonymous. We'll notify you when Omni MedSci, Inc. files another patent-infringement lawsuit. One-click unsubscribe from any alert.
Omni MedSci infringement action against Fossil Group, Inc. et al. in the Eastern District of Texas, filed June 12, 2026. Pending; the narrative does not list asserted patents for this case.
Omni MedSci infringement action against OnePlus Technology (Shenzhen) Co., Ltd. in the Eastern District of Texas, filed June 12, 2026. Consolidated for pretrial issues under 2:26-cv-00289 per a June 17, 2026 order; pending. The narrative does not list asserted patents for this case.
Omni MedSci asserts eight patents, including US 12,588,820, against Samsung. The '820 is asserted at least in claims 9 and 10 against Samsung's Galaxy XR headset based on direct time-of-flight sensing. Relief sought includes declaratory judgment of infringement, damages, permanent injunction, and attorney's fees.
Omni MedSci infringement action against Oura Health Oy in the Eastern District of Texas, filed April 10, 2026. It is the lead consolidated case for the 2026 E.D. Tex. filings; pending. The narrative does not list asserted patents for this case.
Omni MedSci, Inc. filed a patent infringement lawsuit in the Eastern District of Texas against Samsung, Fossil, OnePlus, and Ōura Health Oy, asserting patent 12193790. The case is pending, with defendants having moved for a stay.
Omni MedSci sued Apple in N.D. Cal. involving US 10,517,484. No final district-court judgment on the '484 patent was verified; validity was resolved through PTAB IPR2021-00453.
Omni MedSci, Inc. sued WHOOP, Inc. in the District of Delaware for patent infringement related to patent 12193790. WHOOP, Inc. has filed a motion to stay the case pending PTAB review proceedings.
District court action in the Omni MedSci v. Apple litigation; claim construction order issued June 24, 2019. Narrative does not identify asserted patents and states US 9,995,722 was not confirmed as asserted.
District court action in the Omni MedSci v. Samsung litigation. No asserted patents identified; US 9,995,722 not confirmed as asserted.
District court action in the Omni MedSci v. WHOOP litigation. No asserted patents identified; US 9,995,722 not confirmed as asserted.
Patent infringement suit filed in 2018 by Omni MedSci against Apple; the '040 patent was among the asserted patents. The case was transferred to the N.D. Cal. on October 2, 2019.
Omni MedSci infringement action against Apple Inc. The narrative states it asserted the '533, '040, '286, and '698 patents and proceeded through Omni MedSci, Inc. v. Apple Inc. (Fed. Cir. 2021) on standing/assignment before concluding; the '311 patent is not confirmed as asserted.